Dioscin (Synonyms: 薯蕷皂甙; Collettiside III; CCRIS 4123)

目錄號(hào): HY-N0124 純度: 99.95%: FAQs
Data Sheet SDS COA 產(chǎn)品使用指南

摩爾計(jì)算器

Dioscin (CCRIS 4123; Collettiside III) 是天然的植物來源的甾體皂苷，針對(duì)多種癌細(xì)胞有較好的抗癌活性。Dioscin 可造成 HeLa 和 SiHa 細(xì)胞的 DNA 損傷，并誘導(dǎo)細(xì)胞凋亡 (apoptosis)。Dioscin 調(diào)節(jié) ROS 介導(dǎo)的 DNA 損傷和線粒體信號(hào)通路，發(fā)揮抗癌活性。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Dioscin Chemical Structure

CAS No. : 19057-60-4

1. 客戶無需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2. 同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3. 試用裝只面向終端客戶。

規(guī)格	價(jià)格	是否有貨
10 mM * 1 mL in DMSO	￥459	In-stock
5 mg	￥400	In-stock
10 mg	￥480	In-stock
25 mg	￥624	In-stock
50 mg	￥748	In-stock
100 mg	￥898	In-stock
200 mg		詢價(jià)
500 mg		詢價(jià)

or 大包裝詢價(jià)

* Please select Quantity before adding items.

Customer Review

Other Forms of Dioscin:

Dioscin (Standard) 詢價(jià)

MCE 顧客使用本產(chǎn)品發(fā)表的 10 篇科研文獻(xiàn)

•Br J Pharmacol. 2021 Apr 26. [Abstract]
•Antioxidants (Basel). 2024 May 29;13(6):667. [Abstract]
•Int Immunopharmacol. 2023 Feb 19;117:109839. [Abstract]
•Front Pharmacol. 2020 Jul 24;11:1099. [Abstract]
•Molecules . 2019 Jun 14;24(12):2222. [Abstract]
•J Cancer. 2023 Jul 9;14(11):2027-2038. [Abstract]

•Med Chem Res. 2021 Mar 17.
•Mol Med Rep. 2017 Oct;16(4):4922-4926. [Abstract]
•Folia Histochem Cytobiol. 2024 Jul 23. [Abstract]
•Chem Pharm Bull (Tokyo). 2020;68(8):717-725. [Abstract]

: Dioscin purchased from MCE. Usage Cited in: Int Immunopharmacol. 2023 Feb 19;117:109839. [Abstract]; Dioscin-Medium group (5 mg/kg; p.o.; every-two days for 12 weeks) profoundly inhibits the phosphorylation of NF-?B in mice (Fig H and I). Dioscin-Low (Dio-L, 2.5 mg/kg), Dioscin-Medium (Dio-M, 5 mg/kg) and Dioscin-High (Dio-H, 10 mg/Kg).

: Dioscin purchased from MCE. Usage Cited in: Mol Med Rep. 2017 Oct;16(4):4922-4926. [Abstract]; Dioscin concentrations of 0.5, 1, 5, 10 and 25 μg/mL promotes the expression of ALP and inhibits the expression of LC3B in MC3T3-E1 cells, in a concentration-dependent manner.

Dioscin 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

生物活性
純度 & 產(chǎn)品資料
參考文獻(xiàn)

生物活性

Dioscin (CCRIS 4123; Collettiside III) is a natural plant-derived steroidal saponin that has good anti-cancer activity against a variety of cancer cells. Dioscin causes DNA damage and induces apoptosis in HeLa and SiHa cells. Dioscin regulates ROS-mediated DNA damage and mitochondrial signaling pathways, exerting anticancer activity^[1]^[2]^[3]^[4]^[5]^[6].

細(xì)胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A2780	IC₅₀	0.581 μM Compound: Dioscin	Cytotoxicity against human A2780 cells by MTT assay Cytotoxicity against human A2780 cells by MTT assay	[PMID: 21482468]
A2780	IC₅₀	0.87 μM Compound: Dioscin	Cytotoxicity against human A2780 cells by MTT assay Cytotoxicity against human A2780 cells by MTT assay	[PMID: 22429911]
A2780	IC₅₀	4.46 μM Compound: Dioscin	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	[PMID: 19362474]
A549	IC₅₀	0.454 μM Compound: Dioscin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 21482468]
A549	IC₅₀	0.7 μM Compound: Dioscin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19362474]
A549	IC₅₀	0.81 μM Compound: Dioscin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 22429911]
A549	IC₅₀	4.2 μM Compound: dioscin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 16905317]
BC1 cell line	IC₅₀	3.8 μM Compound: 2	Cytotoxicity against human BC1 cells after 72 hrs by SRB assay Cytotoxicity against human BC1 cells after 72 hrs by SRB assay	[PMID: 12088425]
Bel-7402	IC₅₀	0.23 μM Compound: Dioscin	Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay	[PMID: 19362474]
Bel-7402	IC₅₀	0.81 μM Compound: Dioscin	Cytotoxicity against human Bel7402 cells by MTT assay Cytotoxicity against human Bel7402 cells by MTT assay	[PMID: 22429911]
Bel-7402	IC₅₀	0.93 μM Compound: Dioscin	Cytotoxicity against human Bel7402 cells by MTT assay Cytotoxicity against human Bel7402 cells by MTT assay	[PMID: 21482468]
BGC-823	IC₅₀	0.268 μM Compound: Dioscin	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 21482468]
BGC-823	IC₅₀	1.08 μM Compound: Dioscin	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 22429911]
BGC-823	IC₅₀	2 μM Compound: dioscin	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 16905317]
BXPC-3	IC₅₀	0.7 μM Compound: Dioscin	Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay	[PMID: 19362474]
BXPC-3	GI₅₀	1.3 μg/mL Compound: 4, dioscin	Growth inhibition of humanBxPC3 cells after 48 hrs Growth inhibition of humanBxPC3 cells after 48 hrs	[PMID: 15921418]
Capan-2	IC₅₀	0.05 μM Compound: Dioscin	Cytotoxicity against human Capan2 cells after 72 hrs by MTT assay Cytotoxicity against human Capan2 cells after 72 hrs by MTT assay	[PMID: 19362474]
Col2	IC₅₀	2.8 μM Compound: 2	Cytotoxicity against human Col2 cells after 72 hrs by SRB assay Cytotoxicity against human Col2 cells after 72 hrs by SRB assay	[PMID: 12088425]
DU-145	GI₅₀	> 10 μg/mL Compound: 4, dioscin	Growth inhibition of human DU145 cells after 48 hrs Growth inhibition of human DU145 cells after 48 hrs	[PMID: 15921418]
HCT-8	IC₅₀	0.34 μM Compound: Dioscin	Cytotoxicity against human HCT8 cells by MTT assay Cytotoxicity against human HCT8 cells by MTT assay	[PMID: 22429911]
HCT-8	IC₅₀	0.351 μM Compound: Dioscin	Cytotoxicity against human HCT8 cells by MTT assay Cytotoxicity against human HCT8 cells by MTT assay	[PMID: 21482468]
HCT-8	IC₅₀	0.56 μM Compound: Dioscin	Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay	[PMID: 19362474]
HeLa	IC₅₀	0.5 μM Compound: Dioscin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 22429911]
HGC-27	IC₅₀	5.9 μM Compound: dioscin	Cytotoxicity against human HGC27 cells by MTT assay Cytotoxicity against human HGC27 cells by MTT assay	[PMID: 16905317]
HL-60	IC₅₀	2 μM Compound: 6	Cytotoxicity against human HL60 cells after 72 hrs by MTT assay Cytotoxicity against human HL60 cells after 72 hrs by MTT assay	[PMID: 12828464]
HL-60	IC₅₀	3.8 μM Compound: 1	Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 22405922]
K562	IC₅₀	4.7 μM Compound: 1	Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 23621869]
K562/Adr	IC₅₀	3.3 μM Compound: 1	Cytotoxicity against human K562/ADR cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human K562/ADR cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 23621869]
KB	IC₅₀	0.53 μM Compound: Dioscin	Cytotoxicity against human KB cells by MTT assay Cytotoxicity against human KB cells by MTT assay	[PMID: 22429911]
KB	IC₅₀	20.7 μM Compound: 2	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 12088425]
KB	ED₅₀	21 μM Compound: 8	Growth inhibition of human KB cells xenografted in ip dosed NCr nu/nu mouse administered once daily from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test Growth inhibition of human KB cells xenografted in ip dosed NCr nu/nu mouse administered once daily from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test	[PMID: 19161316]
KB-V1	IC₅₀	> 23 μM Compound: 2	Cytotoxicity against human KBV1 cells after 72 hrs by SRB assay Cytotoxicity against human KBV1 cells after 72 hrs by SRB assay	[PMID: 12088425]
KETR3	IC₅₀	0.447 μM Compound: Dioscin	Cytotoxicity against human Ketr3 cells by MTT assay Cytotoxicity against human Ketr3 cells by MTT assay	[PMID: 21482468]
KM-20L2	GI₅₀	1.3 μg/mL Compound: 4, dioscin	Growth inhibition of human KM20L2 cells after 48 hrs Growth inhibition of human KM20L2 cells after 48 hrs	[PMID: 15921418]
LNCaP	IC₅₀	1.7 μM Compound: 2	Cytotoxicity against human LNCAP cells after 72 hrs by SRB assay Cytotoxicity against human LNCAP cells after 72 hrs by SRB assay	[PMID: 12088425]
LNCaP	ED₅₀	1.7 μM Compound: 8	Growth inhibition of human LNCAP cells xenografted in ip dosed NCr nu/nu mouse administered once daily from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test Growth inhibition of human LNCAP cells xenografted in ip dosed NCr nu/nu mouse administered once daily from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test	[PMID: 19161316]
Lu1	IC₅₀	1.2 μM Compound: 2	Cytotoxicity against human Lu1 cells after 72 hrs by SRB assay Cytotoxicity against human Lu1 cells after 72 hrs by SRB assay	[PMID: 12088425]
Lu1	ED₅₀	1.2 μM Compound: 8	Growth inhibition of human Lu1 cells xenografted in ip dosed NCr nu/nu mouse administered once daily from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test Growth inhibition of human Lu1 cells xenografted in ip dosed NCr nu/nu mouse administered once daily from day 3 to 6 after implantation measured on day 7 by MTT-based hollow-fiber test	[PMID: 19161316]
MCF7	GI₅₀	0.68 μg/mL Compound: 4, dioscin	Growth inhibition of human MCF7 cells after 48 hrs Growth inhibition of human MCF7 cells after 48 hrs	[PMID: 15921418]
MCF7	IC₅₀	0.879 μM Compound: Dioscin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 21482468]
MCF7	IC₅₀	1.03 μM Compound: Dioscin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 19362474]
MCF7	IC₅₀	22.4 μM Compound: 2	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 12088425]
NCI-H460	GI₅₀	1.8 μg/mL Compound: 4, dioscin	Growth inhibition of human NCI-H460 cells after 48 hrs Growth inhibition of human NCI-H460 cells after 48 hrs	[PMID: 15921418]
NCI-H460	IC₅₀	4.56 μM Compound: 12	Cytotoxicity against human NCI-H460 cells incubated for 24 hrs by MTT assay Cytotoxicity against human NCI-H460 cells incubated for 24 hrs by MTT assay	[PMID: 28606759]
P388	ED₅₀	> 10 μg/mL Compound: 4, dioscin	Growth inhibition of mouse P388 cells after 48 hrs Growth inhibition of mouse P388 cells after 48 hrs	[PMID: 15921418]
P388	IC₅₀	21.9 μM Compound: 2	Cytotoxicity against mouse P388 cells after 72 hrs by SRB assay Cytotoxicity against mouse P388 cells after 72 hrs by SRB assay	[PMID: 12088425]
PANC-1	IC₅₀	0.81 μM Compound: Dioscin	Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay	[PMID: 19362474]
SF-268	GI₅₀	1.2 μg/mL Compound: 4, dioscin	Growth inhibition of human SF268 cells after 48 hrs Growth inhibition of human SF268 cells after 48 hrs	[PMID: 15921418]
SK-MEL-2	IC₅₀	1.8 μM Compound: 2	Cytotoxicity against human SK-MEL-2 cells after 72 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells after 72 hrs by SRB assay	[PMID: 12088425]
SW1990	IC₅₀	0.5 μM Compound: Dioscin	Cytotoxicity against human SW1990 cells after 72 hrs by MTT assay Cytotoxicity against human SW1990 cells after 72 hrs by MTT assay	[PMID: 19362474]
SW626	IC₅₀	3.1 μM Compound: 2	Cytotoxicity against human SW626 cells after 72 hrs by SRB assay Cytotoxicity against human SW626 cells after 72 hrs by SRB assay	[PMID: 12088425]

體外研究
(In Vitro)

Dioscin (1.25-5 μg/mL; 6-24 h) 增加 HeLa 和 SiHa 細(xì)胞內(nèi)鈣離子水平，并誘導(dǎo)細(xì)胞凋亡^[4]。
Dioscin (1.25-5 μg/mL; 6-24 h) Dioscin 上調(diào) Bak、Bax、Bid、p53、caspase-3、caspase-9 的蛋白水平，并下調(diào) Bcl-2 和 Bcl-xl 的蛋白水平^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內(nèi)研究
(In Vivo)

Dioscin (75-300 mg/kg, 10 mL/kg; oral gavage；90 天) 對(duì)雌性大鼠無亞慢性毒性，對(duì)雄性大鼠有輕微的亞慢性毒性。Dioscin 造成雄性大鼠輕微的胃腸道擴(kuò)張，并且在血液學(xué)評(píng)估中表現(xiàn)出溶血性貧血^[5]。
Dioscin 通過抑制氧化-硝化應(yīng)激、炎癥和細(xì)胞凋亡，可減輕大鼠肝缺血再灌注損傷^[6]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

869.04

Formula

C₄₅H₇₂O₁₆

CAS 號(hào)

19057-60-4

性狀

固體

顏色

White to off-white

中文名稱

薯蕷皂甙；薯蕷皂甙；薯蕷皂苷

結(jié)構(gòu)分類

Steroids

初始來源

運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.

儲(chǔ)存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性數(shù)據(jù)

細(xì)胞實(shí)驗(yàn)：

DMSO 中的溶解度 : ≥ 100 mg/mL (115.07 mM; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響，請(qǐng)使用新開封的 DMSO)

* "≥" means soluble, but saturation unknown.

配制儲(chǔ)備液

濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg

1 mM	1.1507 mL	5.7535 mL	11.5070 mL
5 mM	0.2301 mL	1.1507 mL	2.3014 mL
10 mM	0.1151 mL	0.5753 mL	1.1507 mL

查看完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用， -20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用。

摩爾計(jì)算器
稀釋計(jì)算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

濃度 _(start)

體積 _(start)

濃度 _(final)

體積 _(final)

動(dòng)物實(shí)驗(yàn)：

請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥方式選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液，再依次添加助溶劑：
——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

方案一

請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.25 mg/mL (2.59 mM); 澄清溶液

此方案可獲得 ≥ 2.25 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 22.5 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水定容至 1 mL。
生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
方案二

請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.25 mg/mL (2.59 mM); 澄清溶液

此方案可獲得 ≥ 2.25 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 22.5 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液中，混合均勻。
2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
方案三

請(qǐng)依序添加每種溶劑： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.25 mg/mL (2.59 mM); 澄清溶液

此方案可獲得 ≥ 2.25 mg/mL（飽和度未知）的澄清溶液，此方案實(shí)驗(yàn)周期在半個(gè)月以上的動(dòng)物實(shí)驗(yàn)酌情使用。
以 1 mL 工作液為例，取 100 μL 22.5 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL玉米油中，混合均勻。

以下溶解方案，請(qǐng)直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶。

方案一

請(qǐng)依序添加每種溶劑： 0.5% CMC-Na/saline water
Solubility: 5 mg/mL (5.75 mM); 懸濁液; 超聲助溶

動(dòng)物溶解方案計(jì)算器

請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息：

給藥劑量

mg/kg

動(dòng)物的平均體重

每只動(dòng)物的給藥體積

μL

動(dòng)物數(shù)量

只

由于實(shí)驗(yàn)過程有損耗，建議您多配一只動(dòng)物的量

請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成：

DMSO +

Tween-80 +

Saline

如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。

方案所需 助溶劑 包括：DMSO，，均可在 MCE 網(wǎng)站選購(gòu)。，Tween 80，均可在 MCE 網(wǎng)站選購(gòu)。

計(jì)算結(jié)果

工作液所需濃度 : mg/mL

儲(chǔ)備液配制方法 : mg 藥物溶于 μL DMSO（母液濃度為 mg/mL）。

您所需的儲(chǔ)備液濃度超過該產(chǎn)品的實(shí)測(cè)溶解度，以下方案僅供參考，如有需要，請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。

動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。

連續(xù)給藥周期超過半月以上，請(qǐng)謹(jǐn)慎選擇該方案。

請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱（超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。

純度 & 產(chǎn)品資料

純度: 99.95%

選擇批次：

Data Sheet (644 KB) SDS (393 KB)

COA (293 KB) HNMR (340 KB) RP-HPLC (213 KB) MS (69 KB)

產(chǎn)品使用指南 (1538 KB)

參考文獻(xiàn)

[1]. Chen J, et al. Dioscin-induced apoptosis of human LNCaP prostate carcinoma cells through activation of caspase-3 and modulation of Bcl-2 protein family. J Huazhong Univ Sci Technolog Med Sci. 2014 Feb;34(1):125-30. [Content Brief]

[2]. Qu X, et al. Dioscin inhibits osteoclast differentiation and bone resorption though down-regulating the Akt signaling cascades. Biochem Biophys Res Commun. 2014 Jan 10;443(2):658-65. [Content Brief]

[3]. Qin J, et al. Dioscin prevents the mitochondrial apoptosis and attenuates oxidative stress in cardiac H9c2 cells. Drug Res (Stuttg). 2014 Jan;64(1):47-52. [Content Brief]

[4]. Zhao X, et al. Dioscin Induces Apoptosis in Human Cervical Carcinoma HeLa and SiHa Cells through ROS-Mediated DNA Damage and the Mitochondrial Signaling Pathway. Molecules. 2016 Jun 4;21(6):730. [Content Brief]

[5]. Xu T, et al. A 90-day subchronic toxicological assessment of dioscin, a natural steroid saponin, in Sprague-Dawley rats. Food Chem Toxicol. 2012 May;50(5):1279-87. [Content Brief]

[6]. Tao X, et al. Dioscin attenuates hepatic ischemia-reperfusion injury in rats through inhibition of oxidative-nitrative stress, inflammation and apoptosis. Transplantation. 2014 Sep 27;98(6):604-11. [Content Brief]

Dioscin 相關(guān)分類

完整儲(chǔ)備液配制表

可選溶劑	濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.1507 mL	5.7535 mL	11.5070 mL	28.7674 mL
	5 mM	0.2301 mL	1.1507 mL	2.3014 mL	5.7535 mL
	10 mM	0.1151 mL	0.5753 mL	1.1507 mL	2.8767 mL
	15 mM	0.0767 mL	0.3836 mL	0.7671 mL	1.9178 mL
	20 mM	0.0575 mL	0.2877 mL	0.5753 mL	1.4384 mL
	25 mM	0.0460 mL	0.2301 mL	0.4603 mL	1.1507 mL
	30 mM	0.0384 mL	0.1918 mL	0.3836 mL	0.9589 mL
	40 mM	0.0288 mL	0.1438 mL	0.2877 mL	0.7192 mL
	50 mM	0.0230 mL	0.1151 mL	0.2301 mL	0.5753 mL
	60 mM	0.0192 mL	0.0959 mL	0.1918 mL	0.4795 mL
	80 mM	0.0144 mL	0.0719 mL	0.1438 mL	0.3596 mL
	100 mM	0.0115 mL	0.0575 mL	0.1151 mL	0.2877 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

產(chǎn)品名稱：			* 需求量：
* 客戶姓名：			* Email：
* 電話：			* 公司或機(jī)構(gòu)名稱：
留言給我們：

產(chǎn)品名稱：			* Lot #：
* 客戶姓名：			* Email：
電話：			* 部門：
* 公司或機(jī)構(gòu)名稱：
留言給我們：

MedChemExpress (MCE) 只為有資質(zhì)的科研機(jī)構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報(bào)的用途提供醫(yī)藥研發(fā)服務(wù)，不為任何個(gè)人或者非科研性質(zhì)的、非用于藥證申報(bào)使用等其他用途提供服務(wù)。	站點(diǎn)地圖隱私聲明
滬ICP備15051369號(hào)-4 上海工商滬公網(wǎng)安備31011502019417 滬(浦)應(yīng)急管危經(jīng)許[2021]201709(QFYS) 營(yíng)業(yè)執(zhí)照（三證合一）
Copyright ? 2013-2025 MedChemExpress. All Rights Reserved.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Dioscin (Synonyms: 薯蕷皂甙; Collettiside III; CCRIS 4123)

Customer Review

Other Forms of Dioscin:

MCE 顧客使用本產(chǎn)品發(fā)表的 10 篇科研文獻(xiàn)

Dioscin 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

生物活性

純度 & 產(chǎn)品資料

參考文獻(xiàn)

摩爾計(jì)算器

稀釋計(jì)算器

Dioscin 相關(guān)分類

完整儲(chǔ)備液配制表

Keywords:

您最近查看的產(chǎn)品:

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
郵箱 *

Sorry, but the email address you supplied was invalid.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Dioscin (Synonyms: 薯蕷皂甙; Collettiside III; CCRIS 4123)

Customer Review

Other Forms of Dioscin:

Dioscin 相關(guān)抗體

MCE 顧客使用本產(chǎn)品發(fā)表的 10 篇科研文獻(xiàn)

Dioscin 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

生物活性

純度 & 產(chǎn)品資料

參考文獻(xiàn)

Dioscin 相關(guān)抗體:

摩爾計(jì)算器

稀釋計(jì)算器

Dioscin 相關(guān)分類

完整儲(chǔ)備液配制表

Keywords:

您最近查看的產(chǎn)品:

Request for HNMR Report

Request for HNMR Report

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z